Compare Organon & Co. Common Stock (OGN) vs Pan American Silver Corp. Common Stock (PAAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Pan American Silver Corp. Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Pan American Silver Corp. Common Stock trades at $42.77 (market cap $18.39B). The key difference: Pan American Silver Corp. Common Stock is far larger — about 5.1× Organon & Co. Common Stock's market cap, and Pan American Silver Corp. Common Stock pays the higher dividend (1.65%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Pan American Silver Corp. Common Stock for 2 Days on average.
| OGN | PAAS | |
|---|---|---|
Market Cap | $3.62B | $18.39B |
Volume | 2,892,999 | 3,168,808 |
Sector | Health | Basic Materials |
52-Week High | $13.81 | $68.70 |
52-Week Low | $5.70 | $33.20 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $11.04B | $17.52B |
Dividend Yield | 0.58% | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Pan American Silver (PAAS) trades at $44.53, down 2.58% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results with $978M net income and a 32.03% net margin, and analysts project 2026 revenue growth to $4.3B. Recent news highlights growth from the Timmins and La Colorada projects and a director retirement effective October 31, 2026.
The outlook is positive with a consensus price target of $62.50, implying 40% upside, supported by solid cash flow and reserve growth. Risks include silver price volatility and potential cost pressures. Analyst sentiment is bullish with 52% buy ratings, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Pan American Silver Corp. Common Stock
Pan American Silver is a mining company focused on silver and gold production in the Americas. It also explores and develops precious metals properties.
Read more on PAAS →
